# Scancell Holdings plc (SCLP.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 10p, market value 134 millionp.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Scancell Holdings plc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 28.5×**. Each dollar of revenue is priced at 28.5×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -16.8%** (5-yr avg -0.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 57.0%**. Scancell Holdings plc keeps 57.0% of revenue after the direct cost of what it sells.
- **Operating margin: -722.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -260.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: 320.0%**. A 320.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 588.6%**. Return on all capital, debt included, is 588.6%: comfortably above what that capital costs.
- **Return on assets: -92.4%**. Each dollar of assets produces -92.4% of profit.

## Growth
- **EPS growth (1 yr): -85.3%**. Earnings per share fell 85.3%.

## Financial health
- **Net debt / EBITDA: 0.0×**. It would take 0.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -10.3×**. Operating profit covers interest only -10.3×: fragile.
- **Current ratio: 0.77** (quick 0.77). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 0.47**. A Z-score of 0.47 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Scancell Holdings plc does not currently pay a dividend, but it returned -16.4% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover Scancell Holdings plc; the consensus is strong_buy, with an average price target of 26p (+158% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 9.6%** (YTD -3.1%, 3-mo -55.9%). The shares are up 9.6% over twelve months including dividends.
- **From 52-week high: -66.4%** (26.0% above the low). Trading 66% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 33**. An RSI of 33 is neutral.
- **Beta (1 yr): -0.07** (volatility 61%). Beta of -0.07 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SCLP.L · Page: https://foliofundamentals.com/stocks/sclp.l

Not investment advice.